Ironwood Pharmaceuticals Debt-to-Equity Ratio Growth & History (IRWD)
Ironwood Pharmaceuticals's debt-to-equity ratio was 0.64 for fiscal 2022.
View full Ironwood Pharmaceuticals company overviewIronwood Pharmaceuticals annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2022 | 2022-12-31 | 0.64 | 0.05 | +7.62% |
| 2021 | 2021-12-31 | 0.59 | −6.65 | −91.82% |
| 2020 | 2020-12-31 | 7.24 | — | — |
| 2017 | 2017-12-31 | 25.72 | 25.62 | +27096.01% |
| 2016 | 2016-12-31 | 0.09 | −2.26 | −95.98% |
| 2015 | 2015-12-31 | 2.35 | 2.31 | +5489.83% |
| 2014 | 2014-12-31 | 0.04 | −0.07 | −62.39% |
| 2013 | 2013-12-31 | 0.11 | 0.11 | +2730.04% |
| 2012 | 2012-12-31 | 0.00 | −0.00 | −33.75% |
| 2011 | 2011-12-31 | 0.01 | 0.00 | +61.24% |
| 2010 | 2010-12-31 | 0.00 | — | — |
Ironwood Pharmaceuticals quarterly debt-to-equity ratio
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2023 | 2023-03-31 | 0.59 | −0.45 | −43.26% |
| Q4 2022 | 2022-12-31 | 0.64 | 0.05 | +7.62% |
| Q3 2022 | 2022-09-30 | 0.70 | −0.12 | −14.25% |
| Q2 2022 | 2022-06-30 | 0.78 | −0.14 | −15.42% |
| Q1 2022 | 2022-03-31 | 1.04 | −3.13 | −75.11% |
| Q4 2021 | 2021-12-31 | 0.59 | −6.65 | −91.82% |
| Q3 2021 | 2021-09-30 | 0.82 | −75.13 | −98.92% |
| Q2 2021 | 2021-06-30 | 0.92 | — | — |
| Q1 2021 | 2021-03-31 | 4.17 | — | — |
| Q4 2020 | 2020-12-31 | 7.24 | — | — |
| Q3 2020 | 2020-09-30 | 75.95 | — | — |
| Q4 2017 | 2017-12-31 | 25.72 | 25.62 | +27096.01% |
| Q2 2017 | 2017-06-30 | 1.05 | 1.01 | +3115.34% |
| Q1 2017 | 2017-03-31 | 0.19 | 0.16 | +527.52% |
| Q4 2016 | 2016-12-31 | 0.09 | −2.26 | −95.98% |
| Q3 2016 | 2016-09-30 | 0.06 | 0.03 | +82.55% |
| Q2 2016 | 2016-06-30 | 0.03 | 0.01 | +44.41% |
| Q1 2016 | 2016-03-31 | 0.03 | −0.02 | −41.25% |
| Q4 2015 | 2015-12-31 | 2.35 | 2.31 | +5489.83% |
| Q3 2015 | 2015-09-30 | 0.03 | −0.00 | −8.59% |
| Q2 2015 | 2015-06-30 | 0.02 | −0.01 | −24.99% |
| Q1 2015 | 2015-03-31 | 0.05 | 0.03 | +138.86% |
| Q4 2014 | 2014-12-31 | 0.04 | −0.07 | −62.39% |
| Q3 2014 | 2014-09-30 | 0.04 | −0.02 | −31.50% |
| Q2 2014 | 2014-06-30 | 0.03 | 0.03 | +895.11% |
| Q1 2014 | 2014-03-31 | 0.02 | 0.01 | +149.66% |
| Q4 2013 | 2013-12-31 | 0.11 | 0.11 | +2730.04% |
| Q3 2013 | 2013-09-30 | 0.05 | 0.05 | +1432.36% |
| Q2 2013 | 2013-06-30 | 0.00 | −0.00 | −39.33% |
| Q1 2013 | 2013-03-31 | 0.01 | 0.00 | +97.05% |
| Q4 2012 | 2012-12-31 | 0.00 | −0.00 | −33.75% |
| Q3 2012 | 2012-09-30 | 0.00 | −0.00 | −43.93% |
| Q2 2012 | 2012-06-30 | 0.00 | −0.00 | −15.78% |
| Q1 2012 | 2012-03-31 | 0.00 | — | — |
| Q4 2011 | 2011-12-31 | 0.01 | 0.00 | +61.24% |
| Q3 2011 | 2011-09-30 | 0.01 | — | — |
| Q2 2011 | 2011-06-30 | 0.01 | — | — |
| Q4 2010 | 2010-12-31 | 0.00 | — | — |
Ironwood Pharmaceuticals debt-to-equity ratio trends
Over the last five fiscal years, Ironwood Pharmaceuticals's debt-to-equity ratio decreased from 25.72 to 0.64, a change of −25.08. The latest reported quarter, Q1 2023, shows 0.59.
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ironwood Pharmaceuticals source filings ↗